Company Encyclopedia
View More
name
KPC
600422.SH
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections and others. The company’s brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco. It markets artemisinin antimalarials, generic drugs, and medical apparatus.
3.157 T
600422.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking104/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.72%B
    • Profit Margin6.43%B
    • Gross Margin38.72%B
  • Growth ScoreD
    • Revenue YoY-14.70%E
    • Net Profit YoY-21.10%D
    • Total Assets YoY19.80%A
    • Net Assets YoY20.02%A
  • Cash ScoreC
    • Cash Flow Margin1555.00%B
    • OCF YoY-14.70%E
  • Operating ScoreB
    • Turnover0.67B
  • Debt ScoreC
    • Gearing Ratio42.90%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China Resources Pharmaceutical's subsidiary KPC earned 323 million yuan in the first three quarters, a decline of 35.8%

    China Resources Pharmaceutical announced that its subsidiary KPC reported operating revenue of 4.751 billion RMB for the first three quarters, a year-on-year decrease of 18.1%. It recorded a net profit of 323 million RMB, a decline of 35.8%

    AASTOCKS·
    SH
    600422
    +0.23%
    AASTOCKS·
    SH
    600422
    +0.23%

    China Resources Pharmaceutical: KPC's net profit for the first three quarters is 323 million yuan, a year-on-year decrease of 35.76%

    According to the Zhitong Finance APP, China Resources Pharmaceutical announced the performance of KPC for the nine months ending September 30, 2025, with total operating revenue of 4.751 billion yuan, a year-on-year decrease of 18.08%; net profit of 323 million yuan, a year-on-year decrease of 35.76%

    Zhitong·
    SH
    600422
    +0.23%
    Zhitong·
    SH
    600422
    +0.23%

    KPC: Third quarter net profit of 71.0126 million yuan, a year-on-year decrease of 59.03%

    KPC announced that its revenue for the third quarter was 1.4 billion yuan, a year-on-year decrease of 30.19%; net profit was 71.0126 million yuan, a year-on-year decrease of 59.03%. Revenue for the first three quarters was 4.751 billion yuan, a year-on-year decrease of 18.08%; net profit was 269 million yuan, a year-on-year decrease of 39.42%

    Zhitong·
    SH
    600422
    +0.23%
    Zhitong·
    SH
    600422
    +0.23%

    KPC: Plans to use RMB 2.5 billion of idle self-owned funds for investment and financial management

    KPC announced that it plans to use no more than 2.5 billion yuan of idle self-owned funds for medium to low-risk income-generating financial investments. This matter has been reviewed and approved by the board of directors and the board of supervisors and needs to be submitted to the shareholders' meeting for approval. The investment period is within one year from the date of approval by the shareholders' meeting, and the funds can be reused. The company will strictly conduct risk assessment and management in accordance with management regulations

    Zhitong·
    SH
    600422
    +0.23%
    Zhitong·
    SH
    600422
    +0.23%

    KPC: Its three studios under Kunzhong Medicine have been selected for the "National Old Medicine Workers Inheritance Studio" construction project list

    According to news from KPC, the National Administration of Traditional Chinese Medicine recently announced the list of construction projects for the "National Old Medicine Workers Inheritance Studios" for 2025. Kunzhong Medicine, a wholly-owned subsidiary of KPC, successfully qualified with a studio represented by three experts: Li Heng, Ruan Yun, and Yin Huixin. Thus, including the first batch selected in 2024, the "Zhang Yuankun National Old Medicine Workers Inheritance Studio," Kunzhong Medicine has a total of four studios included in the national old medicine workers inheritance studio construction project list

    Zhitong·
    SH
    600422
    +0.23%
    Zhitong·
    SH
    600422
    +0.23%
    © 2025 Longbridge｜Disclaimer